SAN DIEGO , Sept. 23, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is proud to announce the addition of Ms. Wendy S. Johnson as an additional independent member to its Board of

SAN DIEGO , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced the launch of AVISE ® Vasculitis AAV, a new testing panel of individual analytes designed to

SAN DIEGO , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that its management team will participate in the Cantor Fitzgerald Virtual Global Healthcare

SAN DIEGO , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a collaboration with Hospital for Special Surgery (HSS) in New York City .

SAN DIEGO , July 30, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that Ron Rocca , President and Chief Executive Officer of Exagen , will present at the Canaccord

Testing Experiencing Monthly Sequential Improvement Record Gross Margins of 63% SAN DIEGO , July 28, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for

AVISE Tests Now Available to 6 Million Humana Military Beneficiaries SAN DIEGO , July 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that all AVISE test offerings

SAN DIEGO , July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended June 30, 2020 before the market opens

SAN DIEGO , June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced it has entered into an exclusive worldwide license agreement with the Ohio State Innovation

SAN DIEGO , June 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a clinical trial in collaboration with Duke University in Durham, NC .